⏰ deadline January 3, 2027
🖋 📫 submit abstract(s) on #ECMO #ECLS #ECPR #ECCO2r #MCS #PedsICU & more. Save date for EuroELSO conference in 📌 Vienna 🇦🇹
📆 pre-congress: April 28-29
📆 congress: April 29 - May 1
🔎 single-center study
🪦 comparable 90 mortality between IMC/immunocompetent patients
🩸pre #ECLS platelet count emerged as critical risk stratification tool (in immunocompromised patients)
@asaiojournal.bsky.social
🖇️ bit.ly/4inBfLi
🔎 single-center study
🪦 comparable 90 mortality between IMC/immunocompetent patients
🩸pre #ECLS platelet count emerged as critical risk stratification tool (in immunocompromised patients)
@asaiojournal.bsky.social
🖇️ bit.ly/4inBfLi
📌 San José, Costa Rica
📆 November 4-6, 2026
🖇️ congresosusp.com/congreso-elso/
📌 San José, Costa Rica
📆 November 4-6, 2026
🖇️ congresosusp.com/congreso-elso/
🖋️ Message from President
🫁🫀 Circuit Chatter 9th: rescue VP #ECMO after embolectomy for massive PE
📃 News from ELSO Committees
❓ Registry Q&A Corner
🖊️ Survey alley
🖊️ Patient story spotlights
🗺️ #ECLS around the world
🖋️ CEO remarks & more!
🔗 bit.ly/2IR8RCl
🖋️ Message from President
🫁🫀 Circuit Chatter 9th: rescue VP #ECMO after embolectomy for massive PE
📃 News from ELSO Committees
❓ Registry Q&A Corner
🖊️ Survey alley
🖊️ Patient story spotlights
🗺️ #ECLS around the world
🖋️ CEO remarks & more!
🔗 bit.ly/2IR8RCl
@asaiojournal.bsky.social
🖇️ bit.ly/4inBfLi
🔎 single-center study
🪦 comparable 90 mortality between IMC/immunocompetent patients
🩸pre #ECLS platelet count emerged as critical risk stratification tool (in immunocompromised patients)
@asaiojournal.bsky.social
🖇️ bit.ly/4inBfLi
@asaiojournal.bsky.social
🖇️ bit.ly/4inBfLi
⏱️ 20-30' to complete
Links 🖌️
🔗 Adult bit.ly/4rvumf6
🔗 Neo/Peds bit.ly/3T8zzgp
⏱️ 20-30' to complete
Links 🖌️
🔗 Adult bit.ly/4rvumf6
🔗 Neo/Peds bit.ly/3T8zzgp
🫀hemodynamic dysregulation
🩸unique considerations during ECLS: in-parallel circulation + afterload mismatch, concomitant circulatory devices + unloading
💉 catecholamines & derivatives
💉 non-catecholamines
#FOAMcc #FOAMecmo
🔓 rdcu.be/MZ5Q1syp79Ua
🫀hemodynamic dysregulation
🩸unique considerations during ECLS: in-parallel circulation + afterload mismatch, concomitant circulatory devices + unloading
💉 catecholamines & derivatives
💉 non-catecholamines
#FOAMcc #FOAMecmo
🔓 rdcu.be/MZ5Q1syp79Ua
🫀VA #ECMO & #ECPR AS #MCS for patients exhibiting refractory CS or impending CA
🩸advanced reperfusion strategies in patients on VA #ECLS
🫀 alternative percutaneous RV assist devices to provide targeted RV support
🖇️ bit.ly/3W3fWY0
🫀VA #ECMO & #ECPR AS #MCS for patients exhibiting refractory CS or impending CA
🩸advanced reperfusion strategies in patients on VA #ECLS
🫀 alternative percutaneous RV assist devices to provide targeted RV support
🖇️ bit.ly/3W3fWY0
Standardization of In-Vitro Evaluation of Extracorporeal Life Support (ECLS) Devices for Research and Development
ASAIO Journal 72(7): p 525-538, July 2026. | DOI: 10.1097/MAT.0000000000002623
https://ow.ly/SKu850ZWQ4s
#ASAIOJ #ASAIOJournal #ECLS #in-vitrotesting #ECMO
Standardization of In-Vitro Evaluation of Extracorporeal Life Support (ECLS) Devices for Research and Development
ASAIO Journal 72(7): p 525-538, July 2026. | DOI: 10.1097/MAT.0000000000002623
https://ow.ly/SKu850ZWQ4s
#ASAIOJ #ASAIOJournal #ECLS #in-vitrotesting #ECMO
🔍 ELSO Registry analysis including >22.5K adults
🪦 54% pts died during hospitalization; 74% non-survivors vs 54% survivors experienced complications
🧠 neuro complications increased mortality by 3.6
🖇️ bit.ly/4dxaHWu
🔍 ELSO Registry analysis including >22.5K adults
🪦 54% pts died during hospitalization; 74% non-survivors vs 54% survivors experienced complications
🧠 neuro complications increased mortality by 3.6
🖇️ bit.ly/4dxaHWu
🔍 > 7.6K adults with CS from the ELSO Registry, 2015 - 2020; >3K managed with PACs
🖥️ Early on-support PAD potentially important hemodynamic marker during VA #ECLS.
🖇️ bit.ly/4hH8ysu
🔍 ELSO Registry analysis
🖥️ invasive hemodynamic assessed at 24h
PAC alone not associated w lower mortality, but helped assess variables associated with lower mortality: higher PAD at 24h associated w graded increase in mortality.
🖇️ bit.ly/4hH8ysu
🔍 > 7.6K adults with CS from the ELSO Registry, 2015 - 2020; >3K managed with PACs
🖥️ Early on-support PAD potentially important hemodynamic marker during VA #ECLS.
🖇️ bit.ly/4hH8ysu
Share experiece/insights to help ensure that realities of #ECLS practice are reflected in future standards + workforce development efforts
🔗 Adult: bit.ly/4rvumf6
🔗 Neo/Peds: bit.ly/3T8zzgp
Share experiece/insights to help ensure that realities of #ECLS practice are reflected in future standards + workforce development efforts
🔗 Adult: bit.ly/4rvumf6
🔗 Neo/Peds: bit.ly/3T8zzgp
Now, most of the agency’s ongoing data collections and reports appear to be inactive or reduced in scope.
Now, most of the agency’s ongoing data collections and reports appear to be inactive or reduced in scope.
rdcu.be/fszcS
rdcu.be/fszcS
🎥 1️⃣ Foundations of #ECLS research & epidemiology
🎥 2️⃣ ELSO Registry: structure, access, research use
🎥 3️⃣ ECLS Research in low-and middle-income countries
Open #FOAMcc #FOAMecmo
🖇️ bit.ly/4rv2bx4
🎥 1️⃣ Foundations of #ECLS research & epidemiology
🎥 2️⃣ ELSO Registry: structure, access, research use
🎥 3️⃣ ECLS Research in low-and middle-income countries
Open #FOAMcc #FOAMecmo
🖇️ bit.ly/4rv2bx4
🖇️ bit.ly/4iF63Jk
🎯 who benefits❓
⏱️ time-dependent biology of survival: when❓ Cannulation-time gradient
🪟 delivering ecpr within the window: where/how❓
🔮 knowledge gaps/future directions
🖇️ bit.ly/4iF63Jk
🖇️ bit.ly/4iF63Jk
🗺️ study analyzing 5y of routinely collected data from London Ambulance Service
🚑 776 pts met #ECMO eligibility criteria, but only 3% estimated to reach #ECLS-capable centre during operating hours and within 45'
🖇️ bit.ly/4hlPUGC
🗺️ study analyzing 5y of routinely collected data from London Ambulance Service
🚑 776 pts met #ECMO eligibility criteria, but only 3% estimated to reach #ECLS-capable centre during operating hours and within 45'
🖇️ bit.ly/4hlPUGC
https://doi.org/10.1186/s13054-026-06332-y
https://doi.org/10.1186/s13054-026-06332-y
#pharmicu #sccmjc #SCCM
#pharmicu #sccmjc #SCCM